NOVOMEDLINK™

This page contains information about Novo Nordisk products.

NovoLog® reduces nocturnal hypoglycemia versus regular
human insulin1,2

A study of NovoLog® and regular human insulin in basal–bolus use for
patients with tight glycemic control, using NPH insulin as the basal
component, showed a 72% reduction in nocturnal hypoglycemia.

NovoLog® reduces nocturnal hypoglycemic episodes
versus regular human insulin1,2

NovoLog® reduces nocturnal hypoglycemic episodes versus regular human insulin

A 16-week, double-blind, randomized, crossover trial enrolling 155 patients who had
had type 1 diabetes for at least 2 years. Patients taking NPH insulin were randomized
to either NovoLog® or regular human insulin as part of basal–bolus therapy. A 72%
reduction in nocturnal hypoglycemia was documented.1

Related Support

View eSeminar Watch a clinical overview of the efficacy, safety, and tolerability of NovoLog® for adults, children, and adolescents with type 1 diabetes.

Check formulary status Search the current formulary status of NovoLog® in your area to help find coverage for your patients.

Up Next

Learn about dosing and delivery with NovoLog®

References:

  1. Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med. 2004;21(7):769-775.
  2. Data on file, Novo Nordisk, Inc., Princeton, NJ.

  1. NovoLog® (insulin aspart [rDNA origin] injection) Indications and Usage

    NovoLog® is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

    NovoLog® Important Safety Information

    NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients.

    NovoLog® has a more rapid onset and shorter duration of action than regular human insulin. An injection of NovoLog® should be immediately followed by a meal within 5 to 10 minutes. Because of the short duration of action of NovoLog®, a longer-acting insulin also should be used in patients with type 1 diabetes and may be needed in patients with type 2 diabetes. When used in an external subcutaneous insulin infusion pump, NovoLog® should not be mixed with any other insulin or diluent. Hypoglycemia is the most common adverse effect of all insulin therapies, including NovoLog®. The timing of hypoglycemia usually reflects the time-action profile of the administered insulins.

    Any change of insulin dose should be made cautiously and only under medical supervision. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. As with all insulin preparations, the time course of action of NovoLog® may vary in different individuals or at different times in the same individual and is dependent on many conditions, including injection site, local blood supply, temperature, and level of physical activity.

    Needles and NovoLog® FlexPen® must not be shared.

    NovoLog® has not been studied in children with type 2 diabetes or in children with type 1 diabetes under the age of two.

    Severe, life-threatening generalized allergy, including anaphylactic reaction, may occur with any insulin product, including NovoLog®. Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. Insulin, particularly when given intravenously or in settings of poor glycemic control, may cause hypokalemia. Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment.

    Please click hereclick here for Prescribing Information.

NovoLog® is a registered trademark of Novo Nordisk A/S.
NovoMedLink™ is a trademark of Novo Nordisk A/S.